Therefore, the FDA approved pembrolizumab as a second-line treatment option for PD-L1-positive advanced ESCC patients, although the adverse events, such as nausea, vomiting, hypertension, caused by pembrolizumab treatment still need to be further explored. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.